Bristol-myers Squibb Compnay

Mead Johnson & Company

Bristol-myers Company

Bristol-myers

Fabre-kramer Pharmaceuticals, Inc.

Joseph P Yevich

Ronald J Mattson

David W Smith

Davis L Temple, Jr

Walter G Lobeck, Jr

Edward H Ruediger

Katherine S Takaki

Frank D Yocca

James S New

Graham Johnson

Michael Frederick Parker

John D Catt

Daniel J Keavy

Carola Solomon

Pierre Dextraze

James R Epperson

Brett T Watson

Jianqing Li

Robert F Mayol

Jonas A Gylys

Andrew D Williams

Robert R Covington

John E Macor

Jun Yuan

Michael A Poss

Ronnie R Crenshaw

Graham S Poindexter

Harold N Weller, Iii

Bradley C Pearce

David R Tortolani

Marc A Bruce

David P Rotella

George N Karageorge

Derek John Denhart

Keith D Combrink

Michael S Eison

Richard E Gammans

Karen L Leboulluec

Ronald J Matson

Stephen J Kramer

Louis F Fabre

Arlene S Eison

David W Cushman

The S-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The S-isomer may provide reduced potential for adverse effects and a longer duration of action compared to the racemic mixture and with buspirone.

S-6-hydroxy-buspirone

The R-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The R-isomer exhibits greater receptor specificity than the S-isomer and should have reduced potential for the adverse effects associated with the racemic mixture and with buspirone.

R-6-hydroxy-buspirone

Bioactive gepirone metabolites, such as 3-OH gepirone (4,4,-dimethyl-3-hydroxy-1-&lsqb;4-&lsqb;4-(2-pyrimidinyl)-1-piperazinyl&rsqb;butyl&rsqb;-2,6-piperidinedione), and their pharmaceutically acceptable salts and hydrates, can be used to alleviate psychological disorders or the symptoms thereof. The use of these compounds provides advantages over other therapeutic azapirones as they possess superior bioavailability, faster onset of action, and more stable plasma levels when administered to a mammal.

Methods for treating psychological disorders using bioactive metabolites of gepirone

Antipsychotic heterocycle compounds

Compounds of formula I are useful antidepressant agents

Antidepressant heterocyclic compounds

Novel quinazolinone compounds, methods of using such compounds in the treatment of cGMP-associated conditions such as erectile dysfunction, and pharmaceutical compositions containing such compounds.

Quinazolinone inhibitors of cGMP phosphodiesterase

Novel derivatives of benzopyran are provided which are useful as melatonergic agents.

Benzopyran derivatives as melatonergic agents

Novel derivatives of benzodioxa alkylene ethers are provided which are useful as melatonergic agents.

Benzodioxa alkylene ethers as melatonergic agents

Novel derivatives of benzofuran and dihydrobenzofuran are provided which are useful as melatonergic agents.

Benzofuran and dihydrobenzofuran melatonergic agents

There is provided novel biphenylamido derivatives of the formula ##STR1## wherein Z is ##STR2## and Y is H or Z is H and Y is ##STR3## n is 0 or 1; R is C.sub.1-6 alkyl;

Biphenylamido derivatives as melatonergic agents

Novel compound of formula I and pharmaceutically acceptable salts thereof are useful CNS agents: ##STR1## wherein X is CH or N;

Antidepressant 1-arylalkyl-4-(alkoxy pyridinyl)-and

Novel substituted fluorene compunds of Formula I are active as melatonergic agents: ##STR1## wherein: X=H, halogen, OH or OZ;

Ethylamido fluorenes and improved method of making same

Novel substituted carbazole compounds of Formula I are active as melatonergic agents: ##STR1## wherein: R.sub.1 is C(O)R.sub.3 or SO.sub.2 R.sub.4 ;

Ethylamino carbazole melatonergic agents

A series of novel 5-(3,4-diamino-1,2,5-thiadiazole and S-oxide) derivatives of indolylalkylpiperazinyl pyridines and pyrimidines of Formula I are intended for use in the alleviation of vascular headaches. ##STR1## In Formula I, X is selected from S, SO and SO.sub.2.

Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridnyl and

A series of novel 5-cyclobutenedione derivatives of indolylalkylpiperazinyl pyridines and pyrimidines of Formula I are intended for use in the alleviation of vascular headaches. ##STR1##

Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and

Growing community of inventors

Southington, CT, United States of America

Joseph P Yevich